Form 4: Moderna President Trades Shares Under 10b5-1 Plan

Moderna President Stephen Hoge executed a series of transactions involving company stock, including acquisitions and dispositions, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Moderna President Stephen Hoge engaged in several stock transactions on May 15, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan established on November 13, 2025.
• Hoge acquired 37,226 shares of common stock at $19.15 per share and an additional 16,110 shares at the same price.
• He also disposed of 53,336 shares of common stock at $48.40 per share.
• Following these transactions, Hoge beneficially owns 1,477,997 shares directly and holds additional shares indirectly through Valhalla, LLC (4,116 shares) and a trust (151,933 shares).
• Stock options were also exercised, resulting in the acquisition of 37,226 shares and 16,110 shares, with these options being fully vested and exercisable.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves significant share transactions by a key executive, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic trading. The mix of acquisitions and dispositions, coupled with the price difference, warrants attention but does not inherently signal strong positive or negative sentiment without further context.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially less opportunistic trading.
• The acquisition of shares at $19.15 suggests a belief in the stock's future value at that price point.
• The disposition of shares at $48.40 indicates a profitable sale for the reporting person.

Negatives

• A significant number of shares were disposed of, which could be interpreted negatively by the market if not contextualized by the 10b5-1 plan.
• The acquisition price of $19.15 is substantially lower than the disposition price of $48.40, suggesting a potential for significant price volatility or a substantial increase in share value between the plan's adoption and the transaction date.

Risks

• The filing does not explicitly mention any risks associated with these transactions, other than the inherent market risk associated with stock ownership and trading.
• The Rule 10b5-1 plan itself carries the risk of being invalidated if not properly structured and executed according to SEC rules.

Future Outlook

The filing itself is a historical record of transactions and does not contain forward-looking statements or guidance from the company. The Rule 10b5-1 plan implies a pre-determined strategy for future transactions, but specific details beyond the execution date are not provided.

Management Comments

• The reporting person, Stephen Hoge, has disclaimed Section 16 beneficial ownership of shares held in a trust for the benefit of his spouse and children, except to the extent of his pecuniary interest.
• The filing notes that the stock option is fully vested and exercisable.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are closely watched by investors. While these plans are designed to provide an affirmative defense against insider trading allegations, the timing and volume of trades can still influence market perception. Moderna operates in the highly competitive biotechnology sector, where significant stock price movements can occur based on clinical trial results and regulatory approvals.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the sale of shares as a sign of reduced confidence, although the Rule 10b5-1 plan provides a mitigating factor. Acquisitions may signal continued belief in the company's prospects.
• Employees: May observe executive trading patterns as an indicator of company performance and future stock value.
• Management: The transactions reflect the personal financial management of the reporting person.

Next Steps

• The Rule 10b5-1 plan may continue to result in future transactions as per its terms.
• Investors will likely monitor future filings for any further transactions by Mr. Hoge or other Moderna executives.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Trading, Rule 10b5-1, Stock Options, Beneficial Ownership, Stephen Hoge, Stock Transactions, SEC Filing